Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 14.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 260,120 shares of the company's stock after buying an additional 32,492 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.69% of Keros Therapeutics worth $15,105,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of KROS. Intech Investment Management LLC purchased a new stake in shares of Keros Therapeutics during the 3rd quarter valued at approximately $603,000. B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Keros Therapeutics in the third quarter valued at $935,000. LMR Partners LLP acquired a new position in shares of Keros Therapeutics in the 3rd quarter valued at $213,000. KBC Group NV grew its holdings in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after purchasing an additional 432 shares during the period. Finally, Victory Capital Management Inc. purchased a new position in shares of Keros Therapeutics during the 3rd quarter worth $216,000. 71.56% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

KROS has been the topic of a number of recent analyst reports. Wedbush reaffirmed an "outperform" rating and issued a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Bank of America lowered their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a research report on Thursday, September 12th. Guggenheim reissued a "buy" rating and issued a $102.00 target price (up previously from $96.00) on shares of Keros Therapeutics in a research report on Wednesday. Finally, Jefferies Financial Group initiated coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They set a "buy" rating for the company. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $89.56.

Keros Therapeutics Stock Performance

KROS stock traded up $5.39 during mid-day trading on Friday, reaching $70.00. The company had a trading volume of 485,950 shares, compared to its average volume of 422,021. Keros Therapeutics, Inc. has a fifty-two week low of $27.31 and a fifty-two week high of $73.00. The company has a market capitalization of $2.84 billion, a price-to-earnings ratio of -13.44 and a beta of 1.20. The firm has a fifty day simple moving average of $60.32 and a 200 day simple moving average of $52.71.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). The company had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business's quarterly revenue was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.33) earnings per share. As a group, analysts predict that Keros Therapeutics, Inc. will post -5.24 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.